Correction: The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis
Crossref DOI link: https://doi.org/10.1186/s12885-024-11932-4
Published Online: 2024-02-13
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Huang, Xiewei
Yu, Yushuai
Luo, Shiping
Fu, Wenfen
Zhang, Jie
Song, Chuangui
Text and Data Mining valid from 2024-02-13
Version of Record valid from 2024-02-13
Article History
First Online: 13 February 2024